• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@Medipol
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • Scopus İndeksli Yayınlar Koleksiyonu
  • View Item
  •   DSpace@Medipol
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • Scopus İndeksli Yayınlar Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Is it possible to treat osteosarcoma using oligonucleotides confined into controlled release drug delivery systems?

Access

info:eu-repo/semantics/closedAccess

Date

2017

Author

Topuk, Savaş
Akyuva, Yener
Karaaslan, Numan
Mutlu, Çağri Ata
Yılmaz, İbrahim
İşyar, Mehmet
Şirin, Duygu Yaşar
Akkaya, Semih
Özbek, Hanefi
Mahiroğulları, Mahir

Metadata

Show full item record

Citation

Topuk, S., Akyuva, Y., Karaaslan, N., Mutlu, Ç. A., Yılmaz, İ., İşyar, M. ... Mahiroğulları, M. (2017). Is it possible to treat osteosarcoma using oligonucleotides confined into controlled release drug delivery systems? Current Pharmaceutical Biotechnology, 18(6), 516-522. https://dx.doi.org/10.2174/1389201018666170615083455

Abstract

Purpose: The present study aimed to analyze the researches that are at the experimental phase concerning osteosarcoma treatment. The researches included drug delivery systems which allow controlled release and imbue small interfering-/micro-ribonucleic acid. Methods: Without any language preference, we searched US National Library of Medicine National Institutes of Health, Embase, OVID, Cochrane Library database of clinical trials from 1843 to May 25, 2016 and traced all the references of incorporated documents. The data were evaluated using descriptive statistics and the results are shown as frequency (%). Results: We haven't encountered any drug delivery system in which Small interfering ribonucleic acid/ micro ribonucleic acid oligonucleotides were embedded successfully against osteosarcoma. There has been only one research in which hairpin-ribonucleic acid was embedded. Conclusion: It was considered that drug delivery system enabling controlled oligonucleotide release in the treatment period of osteosarcoma was not projected for the clinical use. However, it cannot be neglected that the mentioned experimental studies with regard to osteosarcoma treatment establish the basis of target therapies. The method in question looks promising regarding effective treatment of osteosarcoma in the future.

WoS Q Kategorisi

Q3

xmlui.dri2xhtml.METS-1.0.item-scopusquality

Q2

Source

Current Pharmaceutical Biotechnology

Volume

18

Issue

6

URI

https://dx.doi.org/10.2174/1389201018666170615083455
https://hdl.handle.net/20.500.12511/2272

Collections

  • Makale Koleksiyonu [3440]
  • PubMed İndeksli Yayınlar Koleksiyonu [3746]
  • Scopus İndeksli Yayınlar Koleksiyonu [5786]
  • WoS İndeksli Yayınlar Koleksiyonu [5964]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Guide | Contact |

DSpace@Medipol

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryWoS Q ValueScopus Q ValuePublisherAccess TypeThis CollectionBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryWoS Q ValueScopus Q ValuePublisherAccess Type

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide || Library || İstanbul Medipol University || OAI-PMH ||

Kütüphane ve Dokümantasyon Daire Başkanlığı, İstabul, Turkey
If you find any errors in content, please contact: [email protected]

Creative Commons License
DSpace@Medipol by İstanbul Medipol University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Medipol:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.